{"id":1033,"date":"2015-09-28T18:31:14","date_gmt":"2015-09-28T17:31:14","guid":{"rendered":"http:\/\/blogs.kent.ac.uk\/biosciences\/?p=1033"},"modified":"2015-09-28T18:32:34","modified_gmt":"2015-09-28T17:32:34","slug":"cancer-expert-discovers-novel-pharmacological-action-of-a-candidate-anti-cancer-drug","status":"publish","type":"post","link":"https:\/\/blogs.kent.ac.uk\/biosciences\/2015\/09\/28\/cancer-expert-discovers-novel-pharmacological-action-of-a-candidate-anti-cancer-drug\/","title":{"rendered":"Cancer expert discovers novel pharmacological action of a candidate anti-cancer drug"},"content":{"rendered":"<p>Enzastaurin is a compound that is under clinical investigation as anti-cancer drug. It has been developed as inhibitor of protein kinase beta, a serine\/threonine kinase that is often found highly activated in cancer cells and that contributes to cancer cell aggressiveness. A research team including <a href=\"http:\/\/www.kent.ac.uk\/bio\/profiles\/staff\/michaelis.html\">Martin Michaelis, <\/a>Professor of Cell Biology in Kent, discovered that enzastaurin also inhibits ABCB1 (also known as P-glycoprotein), an efflux pump that transports many different anti-cancer drugs out of cells and that is known to be involved in multi-drug resistance in cancer cells. This offers future opportunities to develop strategies the circumvent common mechanisms of resistance.<\/p>\n<p>The research was published in the journal Oncotarget and is available for open access <a href=\"http:\/\/www.impactjournals.com\/oncotarget\/index.php?journal=oncotarget&amp;page=article&amp;op=view&amp;path[]=2889&amp;path[]=6624\">here.<\/a><\/p>\n<p>&nbsp;<\/p>\n<ul class=\"kent-social-links\"><li><a href='http:\/\/www.facebook.com\/sharer.php?u=https:\/\/blogs.kent.ac.uk\/biosciences\/2015\/09\/28\/cancer-expert-discovers-novel-pharmacological-action-of-a-candidate-anti-cancer-drug\/&amp;t=Cancer expert discovers novel pharmacological action of a candidate anti-cancer drug' target='_blank'><i class='ksocial-facebook' title='Share via Facebook'><\/i><\/a><\/li><li><a href='http:\/\/twitter.com\/home?status=Cancer expert discovers novel pharmacological action of a candidate anti-cancer drug%20https:\/\/blogs.kent.ac.uk\/biosciences\/2015\/09\/28\/cancer-expert-discovers-novel-pharmacological-action-of-a-candidate-anti-cancer-drug\/' target='_blank'><i class='ksocial-twitter' title='Share via Twitter'><\/i><\/a><\/li><li><a href='https:\/\/plus.google.com\/share?url=https:\/\/blogs.kent.ac.uk\/biosciences\/2015\/09\/28\/cancer-expert-discovers-novel-pharmacological-action-of-a-candidate-anti-cancer-drug\/' target='_blank'><i class='ksocial-google-plus' title='Share via Google Plus'><\/i><\/a><\/li><li><a href='http:\/\/linkedin.com\/shareArticle?mini=true&amp;url=https:\/\/blogs.kent.ac.uk\/biosciences\/2015\/09\/28\/cancer-expert-discovers-novel-pharmacological-action-of-a-candidate-anti-cancer-drug\/&amp;title=Cancer expert discovers novel pharmacological action of a candidate anti-cancer drug' target='_blank'><i class='ksocial-linkedin' title='Share via Linked In'><\/i><\/a><\/li><li><a href='mailto:content=https:\/\/blogs.kent.ac.uk\/biosciences\/2015\/09\/28\/cancer-expert-discovers-novel-pharmacological-action-of-a-candidate-anti-cancer-drug\/&amp;title=Cancer expert discovers novel pharmacological action of a candidate anti-cancer drug' target='_blank'><i class='ksocial-email' title='Share via Email'><\/i><\/a><\/li><\/ul>","protected":false},"excerpt":{"rendered":"<p>Enzastaurin is a compound that is under clinical investigation as anti-cancer drug. It has been developed as inhibitor of protein kinase beta, a serine\/threonine kinase &hellip; <a href=\"https:\/\/blogs.kent.ac.uk\/biosciences\/2015\/09\/28\/cancer-expert-discovers-novel-pharmacological-action-of-a-candidate-anti-cancer-drug\/\">Read&nbsp;more<\/a><\/p>\n","protected":false},"author":2767,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[24338,124],"tags":[24332,80442,70],"_links":{"self":[{"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/posts\/1033"}],"collection":[{"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/users\/2767"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/comments?post=1033"}],"version-history":[{"count":1,"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/posts\/1033\/revisions"}],"predecessor-version":[{"id":1034,"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/posts\/1033\/revisions\/1034"}],"wp:attachment":[{"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/media?parent=1033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/categories?post=1033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.kent.ac.uk\/biosciences\/wp-json\/wp\/v2\/tags?post=1033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}